Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Expects Q4 Revenue Jump of up to 26 Percent

NEW YORK (GenomeWeb News) - Bruker BioSciences today said it expects to report fourth-quarter revenue of between $130 million and $135 million — an increase of up to 26 percent over fourth-quarter 2005 revenues.
In a preliminary earnings statement issued today, Bruker said it expects full-year 2006 revenues in the range of $430 million to $435 million — growth of up to 17 percent over full-year 2005 revenues.
Bruker said that it has adjusted its historical financial results to account for its acquisition of Bruker Optics last July. As a result, the company reported pooled revenue of $106.8 million for the fourth quarter of 2005 and $372.3 million for the full year.
Bruker said it expects to report earnings of $.07 to $.09 per share for the fourth quarter.
Bruker said it expects "modest" improvement in income and revenue for the first quarter of 2007.
Bruker's CFO William Knight said the fourth quarter traditionally "has been our best quarter of the year, and our fourth quarter 2006 was particularly strong.
Bruker will release its full results for the fourth quarter and for the full year of 2006 on Feb. 22.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.